Compare Aventis Pharma with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs SUVEN LIFESCIENCES - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA SUVEN LIFESCIENCES SANOFI INDIA/
SUVEN LIFESCIENCES
 
P/E (TTM) x 35.1 19.4 180.3% View Chart
P/BV x 6.1 3.9 155.9% View Chart
Dividend Yield % 1.4 0.5 265.1%  

Financials

 SANOFI INDIA   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
SUVEN LIFESCIENCES
Mar-19
SANOFI INDIA/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs6,840338 2,025.5%   
Low Rs4,630169 2,733.2%   
Sales per share (Unadj.) Rs1,203.152.1 2,308.0%  
Earnings per share (Unadj.) Rs165.36.8 2,419.4%  
Cash flow per share (Unadj.) Rs209.98.6 2,448.7%  
Dividends per share (Unadj.) Rs84.001.50 5,600.0%  
Dividend yield (eoy) %1.50.6 247.6%  
Book value per share (Unadj.) Rs963.665.3 1,475.9%  
Shares outstanding (eoy) m23.03127.28 18.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.84.9 98.0%   
Avg P/E ratio x34.737.1 93.5%  
P/CF ratio (eoy) x27.329.6 92.4%  
Price / Book Value ratio x6.03.9 153.3%  
Dividend payout %50.822.0 231.5%   
Avg Mkt Cap Rs m132,07832,272 409.3%   
No. of employees `0003.31.1 305.1%   
Total wages/salary Rs m4,068661 615.2%   
Avg. sales/employee Rs Th8,393.86,132.2 136.9%   
Avg. wages/employee Rs Th1,232.4611.1 201.7%   
Avg. net profit/employee Rs Th1,153.0803.5 143.5%   
INCOME DATA
Net Sales Rs m27,7086,635 417.6%  
Other income Rs m897242 370.2%   
Total revenues Rs m28,6056,877 415.9%   
Gross profit Rs m6,2351,604 388.7%  
Depreciation Rs m1,027221 463.9%   
Interest Rs m738 18.6%   
Profit before tax Rs m6,0981,587 384.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,292718 319.2%   
Profit after tax Rs m3,806869 437.8%  
Gross profit margin %22.524.2 93.1%  
Effective tax rate %37.645.2 83.1%   
Net profit margin %13.713.1 104.8%  
BALANCE SHEET DATA
Current assets Rs m15,9226,232 255.5%   
Current liabilities Rs m6,2351,490 418.4%   
Net working cap to sales %35.071.5 48.9%  
Current ratio x2.64.2 61.1%  
Inventory Days Days6486 73.6%  
Debtors Days Days2183 25.3%  
Net fixed assets Rs m7,5394,043 186.5%   
Share capital Rs m230127 180.7%   
"Free" reserves Rs m21,9628,183 268.4%   
Net worth Rs m22,1928,310 267.1%   
Long term debt Rs m018 0.0%   
Total assets Rs m29,83910,389 287.2%  
Interest coverage x872.143.1 2,023.2%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.6 145.4%   
Return on assets %12.88.7 146.3%  
Return on equity %17.210.5 163.9%  
Return on capital %27.519.5 141.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,5875,622 135.0%   
Fx outflow Rs m7,1451,799 397.1%   
Net fx Rs m4423,822 11.6%   
CASH FLOW
From Operations Rs m3,739356 1,051.8%  
From Investments Rs m-731-279 262.4%  
From Financial Activity Rs m-1,972-225 876.1%  
Net Cashflow Rs m1,036-148 -699.1%  

Share Holding

Indian Promoters % 0.0 63.4 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 0.0 -  
FIIs % 14.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 36.5 28.8%  
Shareholders   15,184 37,287 40.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  NATCO PHARMA  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 20, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS